Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

Company Overview

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Key Stats

• Today's Range: $2.81 to $3.02
• 50-Day Range: $2.56 to $3.43
• 52-Week Range: $2.56 to $23.80
• Volume: 9,245 shs
• Average Volume: 32,679 shs
• Market Capitalization: $1.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GLMD Stock Analysis - Frequently Asked Questions

How have GLMD shares performed this year?

Galmed Pharmaceuticals' stock was trading at $3.19 at the beginning of the year. Since then, GLMD shares have decreased by 10.0% and is now trading at $2.87.
View the best growth stocks for 2025 here.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its earnings results on Thursday, June, 1st. The biopharmaceutical company reported ($13.08) earnings per share for the quarter, topping the consensus estimate of ($18.00) by $4.92.

When did Galmed Pharmaceuticals' stock split?

Galmed Pharmaceuticals shares reverse split on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol-Myers Squibb (BMY), Plug Power (PLUG), Applied Genetic Technologies (AGTC) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 6/01/2023
• Today: 1/21/2025
• Next Earnings (Estimated): 4/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLMD
• CUSIP: N/A
• CIK: 1595353
• Web: www.galmedpharma.com
• Phone: (723) 693-8448
• Fax: 972-3693-8447
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($16.6561)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,910,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -28.75%
• Return on Assets: -24.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.03
• Quick Ratio: 7.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $33.02 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 640,000
• Free Float: 516,000
• Market Cap: $1.84 million
• Optionable: Not Optionable
• Beta: 0.67